Search

Your search keyword '"Roberto Sanseverino"' showing total 72 results
Start Over Author "Roberto Sanseverino"
72 results on '"Roberto Sanseverino"'

1. Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond

Author

Carlo Buonerba, Concetta Ingenito, Rossella Di Trolio, Francesca Cappuccio, Roberta Rubino, Arianna Piscosquito, Antonio Verde, Ferdinando Costabile, Michela Iuliucci, Felice Crocetto, Francesco Chiancone, Antonio Nacchia, Antonio Campitelli, Luca Scafuri, Roberto Sanseverino, and Giuseppe Di Lorenzo

Subjects
Bladder neoplasms, Diet, Risk factors, Treatment outcomes, Immunotherapy, Micronutrients, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Bladder cancer is considered a global health concern characterized by significant morbidity and mortality rates. The complex relationship between diet and bladder cancer is examined, with a specific focus on the role of diet in risk, outcomes, and treatment efficacy. Attention is drawn to the burgeoning field of immunotherapy in bladder cancer treatment, and the possible influence of diet on its outcomes is explored. While evidence remains limited, prior studies in other cancer types have suggested a potential connection between diet and immunotherapy response. To address this knowledge gap, the ongoing BLOSSOM study is presented, which aims to investigate the link between dietary factors, lifestyle, and the effectiveness of immunotherapy in patients with non-muscle-invasive bladder cancer. Ongoing efforts to decipher the intricate relationship between diet and bladder cancer care are highlighted, emphasizing the quest to unravel the dietary puzzle for the improvement of bladder cancer management.

Published
2024
Full Text
View/download PDF

2. Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review

Author

Achille Aveta, Vincenzo Iossa, Gianluca Spena, Paolo Conforti, Giovanni Pagano, Fabrizio Dinacci, Paolo Verze, Celeste Manfredi, Matteo Ferro, Francesco Lasorsa, Lorenzo Spirito, Luigi Napolitano, Antonio Tufano, Alessandra Fiorenza, Pierluigi Russo, Fabio Crocerossa, Giuseppe Lucarelli, Sisto Perdonà, Roberto Sanseverino, Salvatore Siracusano, Simone Cilio, and Savio Domenico Pandolfo

Subjects
RCC, small renal masses, ablative techniques, recurrence, Science
Abstract

This review focuses on ablative techniques for small renal masses (SRMs), including radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), and irreversible electroporation (IRE), and discusses recurrence management. Through an extensive literature review, we outline the procedures, outcomes, and follow-up strategies associated with each ablative method. The review provides a detailed examination of these techniques—RFA, CA, MWA, and IRE—elucidating their respective outcomes. Recurrence rates vary among them, with RFA and CA showing comparable rates, MWA demonstrating favorable short-term results, and IRE exhibiting promise in experimental stages. For managing recurrences, various strategies are considered, including active surveillance, re-ablation, or salvage surgery. Surveillance is preferred post-RFA and post-CA, due to slow SRM growth, while re-ablation, particularly with RFA and CA, is deemed feasible without additional complications. Salvage surgery emerges as a viable option for larger or resistant tumors. While ablative techniques offer short-term results comparable to surgery, further research is essential to understand their long-term effects fully. Decisions concerning recurrence management should consider individual and tumor-specific factors. Imaging, notably contrast-enhanced ultrasounds, plays a pivotal role in assessing treatment success, emphasizing the necessity of a multidisciplinary approach for optimal outcomes. The lack of randomized trials highlights the need for further research.

Published
2024
Full Text
View/download PDF

3. 'Could Patient Age and Gender, along with Mass Size, Be Predictive Factors for Benign Kidney Tumors?': A Retrospective Analysis of 307 Consecutive Single Renal Masses Treated with Partial or Radical Nephrectomy

Author

Raffaele Baio, Giovanni Molisso, Christian Caruana, Umberto Di Mauro, Olivier Intilla, Umberto Pane, Costantino D’Angelo, Antonio Campitelli, Francesca Pentimalli, and Roberto Sanseverino

Subjects
laparoscopic partial nephrectomy, benign renal mass, tumor size, Technology, Biology (General), QH301-705.5
Abstract

Due to the increased use of common and non-invasive abdominal imaging techniques over the last few decades, the diagnosis of about 60% of renal tumors is incidental. Contrast-enhancing renal nodules on computed tomography are diagnosed as malignant tumors, which are often removed surgically without first performing a biopsy. Most kidney nodules are renal cell carcinoma (RCC) after surgical treatment, but a non-negligible rate of these nodules may be benign on final pathology; as a result, patients undergo unnecessary surgery with an associated significant morbidity. Our study aimed to identify a subgroup of patients with higher odds of harboring benign tumors, who would hence benefit from further diagnostic examinations (such as renal biopsy) or active surveillance. We performed a retrospective review of the medical data, including pathology results, of patients undergoing surgery for solid renal masses that were suspected to be RCCs (for a total sample of 307 patients). Owing to the widespread use of common and non-invasive imaging techniques, the incidental diagnosis of kidney tumors has become increasingly common. Considering that a non-negligible rate of these tumors is found to be benign after surgery at pathological examination, it is crucial to identify features that can correctly diagnose a mass as benign or not. According to our study results, female sex and tumor size ≤ 3 cm were independent predictors of benign disease. Contrary to that demonstrated by other authors, increasing patient age was also positively linked to a greater risk of malign pathology.

Published
2023
Full Text
View/download PDF

4. 'To Be or Not to Be Benign' at Partial Nephrectomy for Presumed RCC Renal Masses: Single-Center Experience with 195 Consecutive Patients

Author

Raffaele Baio, Giovanni Molisso, Christian Caruana, Umberto Di Mauro, Olivier Intilla, Umberto Pane, Costantino D’Angelo, Antonio Campitelli, Francesca Pentimalli, and Roberto Sanseverino

Subjects
laparoscopic partial nephrectomy, benign renal mass, tumor size, Medicine
Abstract

In daily medical practice, an increasing number of kidney masses are being incidentally detected using common imaging techniques, owing to the improved diagnostic accuracy and increasingly frequent use of these techniques. As a consequence, the rate of detection of smaller lesions is increasing considerably. According to certain studies, following surgical treatment, up to 27% of small enhancing renal masses are identified as benign tumors at the final pathological examination. This high rate of benign tumors challenges the appropriateness of surgery for all suspicious lesions, given the morbidity associated with such an intervention. The objective of the present study was, therefore, to determine the incidence of benign tumors at partial nephrectomy (PN) for a solitary renal mass. To meet this end, a total of 195 patients who each underwent one PN for a solitary renal lesion with the intent to cure RCC were included in the final retrospective analysis. A benign neoplasm was identified in 30 of these patients. The age of the patients ranged from 29.9–79 years (average: 60.9 years). The tumor size range was 1.5–7 cm (average: 3 cm). All the operations were successful using the laparoscopic approach. The pathological results were renal oncocytoma in 26 cases, angiomyolipomas in two cases, and cysts in the remaining two cases. In conclusion, we have shown in our present series the incidence rate of benign tumors in patients who have been subjected to laparoscopic PN due to a suspected solitary renal mass. Based on these results, we advise that the patient should be counseled not only about the intra- and post-operative risks of nephron-sparing surgery but also about its dual therapeutic and diagnostic role. Therefore, the patients should be informed of the considerably high probability of a benign histological result.

Published
2023
Full Text
View/download PDF

6. When a Multidisciplinary Approach Is Life-Saving: A Case Report of Cardiogenic Shock Induced by a Large Pheochromocytoma

Author

Raffaele Baio, Tommaso Pagano, Giovanni Molisso, Umberto Di Mauro, Olivier Intilla, Francesco Albano, Fulvio Scarpato, Stefania Giacometti, and Roberto Sanseverino

Subjects
pheochromocytoma, open adrenalectomy, cardiogenic shock, Medicine
Abstract

Background: Pheochromocytoma is known for its instantaneous presentation, especially in the younger population. Hemodynamic instability may be the cause of severe complications and impede patients’ ability to undergo surgical treatment. These tumours are surgically difficult to treat due to the risk of catecholamine release during their manipulations, and when they are large, the tumour size represents an additional challenge. In our report, cardiogenic shock developed due to increases in systemic vascular resistance, and the lesion’s size induced surgeons to perform open surgery. Case presentation: A 46-year-old female patient was admitted to our intensive care unit with hypertension and later cardiogenic shock. Systolic dysfunction was noted, along with severely increased systemic vascular resistance. A CT scan showed a left-sided 8.5 cm adrenal mass, which was confirmed as pheochromocytoma using meta-iodobenzylguanidine scintigraphy. Anaesthesiologists and the surgical team planned an effective strategy of treatment. Given the lesion’s size and its apparent invasion of the neighbouring organs, open adrenalectomy (after prolonged hemodynamic stabilisation) was considered safer. The surgery was successful, and the patient remains free from disease two years after the initial event. Conclusions: Large pheochromocytoma can be safely and effectively treated with open surgery by experienced hands but only by seeking to reach hemodynamic stabilisation and minimising the release of catecholamine before and during surgery.

Published
2022
Full Text
View/download PDF

8. Prognostic impact of ReTURB in high grade T1 primary bladder cancer

Author

Roberto Sanseverino, Giorgio Napodano, Antonio Campitelli, and Maria Addesso

Subjects
Bladder cancer, ReTurb, Prognosis, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Purpose: To evaluate whether pathological outcomes of ReTURB have a prognostic impact on recurrence and progression of primitive T1HG bladder cancer. Material and methods: Patients affected by primitive T1HG TCC of bladder underwent restaging TURB (ReTURB). Patients with muscle invasive disease at ReTURB underwent radical cystectomy; those with non-muscle invasive residual (NMI-RT) and those with no residual tumour (NRT) received an intravesical BCG therapy. We compared recurrence and progression in NMIRT patients and NRT patients at restaging TURB. Patients were followed every 3-6 months with cystoscopy and urine cytology. Results: 212 patients were enrolled in the study. At ReTURB, residual cancer was detected in 92 of 196 (46.9%) valuable patients: 14.3% of these were upstaged to T2. At follow up of 26.3 ± 22.8 months, there were differences in recurrence and progression rates between NRT and NMIRT patients: 26.9% and 45.3% (p < 0.001), 10.6% and 23.4% (p 0.03), respectively. Recurrence-free and progression-free survivals were significantly higher in NRT compared to NMIRT patients: 73.1% and 54.7% (p < 0.001), 89.4% and 76.6 (p 0.03), respectively. Conclusions: ReTURB allows to identify a considerable number of residual and understaged cancer. Patients with NMIRT on ReTURB have worse prognosis than those with NRT in terms of recurrence and progression free survival. These outcomes seem to suggest a prognostic impact of findings on ReTURB that could be a valid tool in management of high grade T1 TCC.

Published
2016
Full Text
View/download PDF

9. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group

Author

Domenico Prezioso, Pasquale Strazzullo, Tullio Lotti, Giampaolo Bianchi, Loris Borghi, Paolo Caione, Marco Carini, Renata Caudarella, Giovanni Gambaro, Marco Gelosa, Andrea Guttilla, Ester Illiano, Marangella Martino, Tiziana Meschi, Piergiorgio Messa, Roberto Miano, Giorgio Napodano, Antonio Nouvenne, Domenico Rendina, Francesco Rocco, Marco Rosa, Roberto Sanseverino, Annamaria Salerno, Sebastiano Spatafora, Andrea Tasca, Andrea Ticinesi, Fabrizio Travaglini, Alberto Trinchieri, Giuseppe Vespasiani, and Filiberto Zattoni

Subjects
Urinary calculi, Dietary treatment, Urinary risk factors, Hypercalciuria, Hyperoxaluria, Hypocitraturia, Children, Elderly, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Objective: Diet interventions may reduce the risk of urinary stone formation and its recurrence, but there is no conclusive consensus in the literature regarding the effectiveness of dietary interventions and recommendations about specific diets for patients with urinary calculi. The aim of this study was to review the studies reporting the effects of different dietary interventions for the modification of urinary risk factors in patients with urinary stone disease. Materials and Methods: A systematic search of the Pubmed database literature up to July 1, 2014 for studies on dietary treatment of urinary risk factors for urinary stone formation was conducted according to a methodology developed a priori. Studies were screened by titles and abstracts for eligibility. Data were extracted using a standardized form and the quality of evidence was assessed. Results: Evidence from the selected studies were used to form evidencebased guideline statements. In the absence of sufficient evidence, additional statements were developed as expert opinions. Conclusions: General measures: Each patient with nephrolithiasis should undertake appropriate evaluation according to the knowledge of the calculus composition. Regardless of the underlying cause of the stone disease, a mainstay of conservative management is the forced increase in fluid intake to achieve a daily urine output of 2 liters. Hypercalciuria: Dietary calcium restriction is not recommended for stone formers with nephrolithiasis. Diets with a calcium content ≥ 1 g/day (and low protein-low sodium) could be protective against the risk of stone formation in hypercalciuric stone forming adults. Moderate dietary salt restriction is useful in limiting urinary calcium excretion and thus may be helpful for primary and secondary prevention of nephrolithiasis. A low-normal protein intake decrease calciuria and could be useful in stone prevention and preservation of bone mass. Omega-3 fatty acids and bran of different origin decreases calciuria, but their impact on the urinary stone risk profile is uncertain. Sports beverage do not affect the urinary stone risk profile. Hyperoxaluria: A diet low in oxalate and/or a calcium intake normal to high (800-1200 mg/day for adults) reduce the urinary excretion of oxalate, conversely a diet rich in oxalates and/or a diet low in calcium increase urinary oxalate. A restriction in protein intake may reduce the urinary excretion of oxalate although a vegetarian diet may lead to an increase in urinary oxalate. Adding bran to a diet low in oxalate cancels its effect of reducing urinary oxalate. Conversely, the addition of supplements of fruit and vegetables to a mixed diet does not involve an increased excretion of oxalate in the urine. The intake of pyridoxine reduces the excretion of oxalate. Hyperuricosuria: In patients with renal calcium stones the decrease of the urinary excretion of uric acid after restriction of dietary protein and purine is suggested although not clearly demonstrated. Hypocitraturia: The administration of alkaline-citrates salts is recommended for the medical treatment of renal stone-formers with hypocitraturia, although compliance to this treatment is limited by gastrointestinal side effects and costs. Increased intake of fruit and vegetables (excluding those with high oxalate content) increases citrate excretion and involves a significant protection against the risk of stone formation. Citrus (lemons, oranges, grapefruit, and lime) and non citrus fruits (melon) are natural sources of dietary citrate, and several studies have shown the potential of these fruits and/or their juices in raising urine citrate levels. Children: There are enought basis to advice an adequate fluid intake also in children. Moderate dietary salt restriction and implementation of potassium intake are useful in limiting urinary calcium excretion whereas dietary calcium restriction is not recommended for children with nephrolithiasis. It seems reasonable to advice a balanced consumption of fruit and vegetables and a low consumption of chocolate and cola according to general nutritional guidelines, although no studies have assessed in pediatric stone formers the effect of fruit and vegetables supplementation on urinary citrate and the effects of chocolate and cola restriction on urinary oxalate in pediatric stone formers. Despite the low level of scientific evidence, a low-protein (< 20 g/day) low-salt (< 2 g/day) diet with high hydration (> 3 liters/day) is strongly advised in children with cystinuria. Elderly: In older patients dietary counseling for renal stone prevention has to consider some particular aspects of aging. A restriction of sodium intake in association with a higher intake of potassium, magnesium and citrate is advisable in order to reduce urinary risk factors for stone formation but also to prevent the loss of bone mass and the incidence of hypertension, although more hemodynamic sensitivity to sodium intake and decreased renal function of the elderly have to be considered. A diet rich in calcium (1200 mg/day) is useful to maintain skeletal wellness and to prevent kidney stones although an higher supplementation could involve an increase of risk for both the formation of kidney stones and cardiovascular diseases. A lower content of animal protein in association to an higher intake of plant products decrease the acid load and the excretion of uric acid has no particular contraindications in the elderly patients, although overall nutritional status has to be preserved.

Published
2015
Full Text
View/download PDF

10. ERRATUM: Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group

Author

Domenico Prezioso, Pasquale Strazzullo, Tullio Lotti, Giampaolo Bianchi, Loris Borghi, Paolo Caione, Marco Carini, Renata Caudarella, Manuel Ferraro, Giovanni Gambaro, Marco Gelosa, Andrea Guttilla, Ester Illiano, Marangella Martino, Tiziana Meschi, Piergiorgio Messa, Roberto Miano, Giorgio Napodano, Antonio Nouvenne, Domenico Rendina, Francesco Rocco, Marco Rosa, Roberto Sanseverino, Annamaria Salerno, Sebastiano Spatafora, Andrea Tasca, Andrea Ticinesi, Fabrizio Travaglini, Alberto Trinchieri, Giuseppe Vespasiani, and Filiberto Zattoni

Subjects
Urinary risk factors, Renal stone formation, CLU Working Group, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Due to a technical error, Dr. Manuel Ferraro was omitted from the author list of this article. The correct author details appear above.

Published
2016
Full Text
View/download PDF

11. Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it

Author

Sebastiano Spatafora, Antonio Casarico, Andrea Fandella, Caterina Galetti, Rodolfo Hurle, Elisa Mazzini, Ciro Niro, Massimo Perachino, Roberto Sanseverino, and Giovanni Luigi Pappagallo

Subjects
Diseases of the genitourinary system. Urology, RC870-923
Abstract

Background: The first Italian national guidelines were developed by the Italian Association of Urologists and published in 2007. Since then, a number of new drugs or classes of drugs have emerged for the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), new data have emerged on medical therapy (monotherapies and combination therapies), new surgical techniques have come into practice, and our understanding of disease pathogenesis has increased. Consequently, a new update of the guidelines has become necessary. Methods: A structured literature review was conducted to identify relevant papers published between 1 August 2006 and 12 December 2010. Publications before or after this timeframe were considered only if they were recognised as important milestones in the field or if the literature search did not identify publications within this timeframe. The quality of evidence and strength of recommendations were determined according to the Grading of Recommendations Assessment, Development and Evaluation framework. Main findings: Decisions on therapeutic intervention should be based on the impact of symptoms on quality of life (QoL) rather than the severity of symptoms (International Prostate Symptom Score (IPSS) score). A threshold for intervention was therefore based on the IPSS Q8, with intervention recommended for patients with a score of at least 4. Several differences in clinical recommendations have emerged. For example, combination therapy with a 5α-reductase inhibitor plus α blocker is now the recommended option for the treatment of patients at risk of BPH progression. Other differences include the warning of potential worsening of cognitive disturbances with use of anticholinergics in older patients, the distinction between Serenoa repens preparations (according to the method of extraction), and the clearly defined threshold of prostate size for performing open surgery (>80 g). While the recommendations included in these guidelines are evidence based, clinical decisions should also be informed by patients’ clinical and physical circumstances, as well as patients’ preferences and actions. Conclusions: These guidelines are intended to assist physicians and patients in the decision-making process regarding the management of LUTS/BPH, and support the process of continuous improvement of the quality of care and services to patients.

Published
2012
Full Text
View/download PDF

13. Physical activity decreases the risk of cancer reclassification in patients on active surveillance: a multicenter retrospective study

Author

Michele Gallucci, Aldo Brassetti, Mariaconsiglia Ferriero, Giorgio Napodano, Leonardo Misuraca, Roberto Sanseverino, Giuseppe Simone, Fabio Badenchini, Riccardo Mastroianni, Flavia Proietti, Gabriele Tuderti, Alfredo Maria Bove, and Umberto Anceschi

Subjects
Male, Cancer Research, medicine.medical_specialty, Urology, 030232 urology & nephrology, Physical activity, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, In patient, Watchful Waiting, Exercise, Aged, Retrospective Studies, business.industry, Prostatic Neoplasms, Cancer, Retrospective cohort study, Middle Aged, Anthropometry, medicine.disease, Log-rank test, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Metabolic syndrome, business
Abstract

BACKGROUND Physical activity (PA) is associated with favorable outcomes in prostate cancer (PCa) patients. We assessed its effect on the risk of PCa reclassification (PCaR) during active surveillance. METHODS Anthropometric, demographic, and clinical data concerning men diagnosed with a low-risk PCa and initially managed with active surveillance at the two participating institutions were retrospectively collected. The Physical Activity Scale for the Elderly (PASE) was used for patients' self-assessment of their daily exercise and their consequent stratification into three groups: sedentary (PASE ≤ 65), moderately active (65

Published
2021

14. Incidence rate and management of diaphragmatic injury during laparoscopic nephrectomies: single-center experience

Author

Raffaele Baio, Giovanni Molisso, Christian Caruana, Oliviero Intilla, Umberto Di Mauro, Umberto Pane, Antonio Campitelli, Francesca Pentimalli, and Roberto Sanseverino

Subjects
Surgery
Abstract

Pneumothorax is a rare complication in laparoscopic renal surgery. However, due to the increasing renal pathologies managed by laparoscopic technique, this infrequent complication is a potential risk. We investigated the incidence rate of this complication in our experience of laparoscopic renal surgery, taking into account the laparoscopic approach, the type of intervention, the character of the pathology (neoplastic or other), the site of the intervention, as well as the localization of the lesion (in case of malignant pathology). About 384 laparoscopic nephrectomies were reviewed at our institution, with a total of four cases (1.04%) of diaphragmatic injury. Diaphragmatic repair was always carried out by intracorporeal suturing, with no complications. Repair of diaphragmatic injuries should always be attempted with intracorporeal suture since this is a safe and effective technique. Then, although in the retroperitoneal approach pneumothorax is more likely, our experience has shown that transperitoneal access is not free from this complication.

Published
2022

15. The autophagy activator Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer’s disease mouse model

Author

Dragomir Milovanovic, Dieter Beule, Roberto Sanseverino, Christian Hoffmann, Stephan J. Sigrist, Lara Fleck, Thomas Conrad, Kiara Freitag, Marina Jendrach, Judith Houtman, Frank L. Heppner, Caroline Braeuning, Benedikt Obermayer, Julia Schulz, and Nele Sterczyk

Subjects
biology, Amyloid, Microglia, Amyloid beta, Autophagy, Inflammasome, Cell biology, Spermidine, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, biology.protein, medicine, Polyamine, Neuroinflammation, medicine.drug
Abstract

Deposition of amyloid beta (Aβ) along with glia cell-mediated neuroinflammation are prominent pathogenic hallmarks of Alzheimer’s disease (AD). In recent years, impairment of autophagy has been found to be another important feature, contributing to AD progression and aging. Therefore, we assessed the effect of the autophagy activator Spermidine, a small body-endogenous polyamine often used as dietary supplement and known to promote longevity, on glia cell-mediated neuroinflammation. Spermidine reduced TLR3- and TLR4- mediated inflammatory processes in microglia and astrocytes by decreasing cytotoxicity, inflammasome activity and NF-κB signaling. In line with these anti-inflammatory effects, oral treatment of the amyloid prone AD-like APPPS1 mice with Spermidine reduced neuroinflammation and neurotoxic soluble Aβ. Mechanistically, single nuclei sequencing revealed microglia as one of the main targets of Spermidine treatment, with increased expression of genes implicated in cell motility and phagocytosis. Thus, Spermidine provides a promising therapeutic potential to target glia cells in AD progression.

Published
2021

16. ‘Burned‑out’ syndrome of testicular teratoma: A case report

Author

Paolo Verze, Roberto Sanseverino, Maria Addesso, Annamaria Libroia, Umberto Di Mauro, Giorgio Napodano, Raffaele Baio, Giovanni Molisso, and O. Intilla

Subjects
endocrine system, Cancer Research, medicine.medical_specialty, burned-out syndrome, medicine.diagnostic_test, business.industry, Cancer, Physical examination, Articles, testicular teratoma, Left Testis, medicine.disease, Occult, Primary tumor, medicine.anatomical_structure, Oncology, Scrotum, Medicine, Germ cell tumors, Radiology, punctuate echogenic foci, business, Testicular cancer
Abstract

The majority of testicular tumors are germ cell tumors (GCTs) which, although rare, frequently present in young adults. In exceptional circumstances, spontaneous regression of the primary tumor occurs. The appellation ‘burned-out’ is applied to situations in which a metastatic GCT is found to be present, accompanied by histological regression of the primary testicular lesion. It is of crucial importance that a clinical examination of the testis is performed, and scrotal sonography is essential in the preliminary diagnosis of such neoplasms. In the present case report, a burned-out, non-seminomatous testicular GCT case is described. A CT scan revealed that a 29-year-old male patient who was experiencing loss of weight and appetite had retroperitoneal and mediastinal masses. A testicular examination did not reveal the presence of any palpable lesion, and an ultrasound examination of the scrotum disclosed a normal left testis and an atrophic right testicle with heterogeneous architecture, but with no evidence of a tumor. Chemotherapy was administered to the patient following surgical intervention into the retroperitoneal and mediastinal mass. It is evident that it remains problematic to accurately differentiate between a primary retroperitoneal tumor and a metastatic testicular tumor with an occult testicular primary or a ‘burned-out’ testicular cancer. The burned-out phenomenon is a rare occurrence, and further research into its pathogenesis is required. Both the rarity of this phenomenon and the difficulties encountered in diagnosis prompted the writing of the present case report, especially considering that teratomas are categorized as belonging to the histology group that shows the least likelihood of regressing.

Published
2021

17. Near-infrared fluorescence imaging with intraoperative administration of indocyanine green for laparoscopic radical prostatectomy: Is it a useful weapon for pelvic lymph node dissection?

Author

Raffaele Baio, Olivier Intilla, Umberto Di Mauro, Umberto Pane, Giovanni Molisso, and Roberto Sanseverino

Subjects
Surgery
Abstract

Near-infrared fluorescence imaging with indocyanine green has emerging applications in urologic surgery. This technology is strongly used in robotic surgery for several ablative and reconstructive procedures. On the contrary, it is not used at all in the urological laparoscopic surgery. To date, bilateral pelvic lymph node dissection represents the most accurate and reliable staging procedure for the detection of lymph node invasion in prostate cancer and bladder cancer. However, it is not devoid of complications. In this field, indocyanine green fluorescence-guided sentinel lymph node identification is an emerging technique, as accurate staging of urologic cancer could be enhanced by an intraoperative lymphatic mapping. Our goal was to show a high spatial resolution, real-time intraoperative imaging technique to recognize the main lymphatic drainage networks, avoiding at same time lymphatic vessel damage. Furthermore, the use of such an imaging system represents an absolute novelty in the field of urological laparoscopy.

Published
2021

18. Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?

Author

Roberto Sanseverino, Giuseppe Di Lorenzo, Francesco Ugliano, Carlo Buonerba, Germano Guerra, Felice Crocetto, Antonella Sciarra, Matteo Ferro, Luca Scafuri, Scafuri, L., Sciarra, A., Crocetto, F., Ferro, M., Buonerba, C., Ugliano, F., Guerra, G., Sanseverino, R., Lorenzo, G. D., Scafuri, Luca, Sciarra, Antonella, Crocetto, Felice, Ferro, Matteo, Buonerba, Carlo, Ugliano, Francesco, Guerra, Germano, Sanseverino, Roberto, and Lorenzo, Giuseppe Di

Subjects
medicine.medical_specialty, Bladder cancer, business.industry, medicine.medical_treatment, Muscle invasive, Urology, adjuvant therapy, Perioperative, bladder cancer, neoadjuvant therapy, medicine.disease, Systemic therapy, Editorial, medicine, Adjuvant therapy, business, Neoadjuvant therapy, Biotechnology, Urothelial carcinoma
Published
2021

19. Single-session laparoscopic cystectomy and nephroureterectomy: is it real and useful choice of treatment or fiction?

Author

U. Mauro, Raffaele Baio, Alessandro Pane, Giovanni Molisso, O. Intilla, and Roberto Sanseverino

Subjects
medicine.medical_specialty, Bladder cancer, medicine.diagnostic_test, AcademicSubjects/MED00910, business.industry, medicine.medical_treatment, medicine.disease, Comorbidity, Surgery, Cystectomy, Laparotomy, Concomitant, medicine, Carcinoma, jscrep/0170, Surgical Technique, Laparoscopy, business, Upper urinary tract
Abstract

Patients with recurrent high grade and/or muscle-invasive bladder cancer and concomitant upper urinary tract disease, e.g. urothelial tumors or afunctional hydronephrotic kidneys, may be candidates for simultaneous laparoscopic cystectomy and nephroureterectomy. So, such patients, especially when affected by multiple comorbidities, can benefit from the avoidance of extended laparotomy. We report our experience with simultaneous laparoscopic radical cystectomy and right nephroureterectomy in a 67-year-old-male patient affected by recurrent polyfocal high grade bladder cancer and an associated right upper tract carcinoma. This laparoscopic approach was technically successful without the need for conversion to open surgery. More than a year after the surgery, the patient is still alive, showing no tumor relapse of at the established instrumental controls. This laparoscopic approach, performed in a single session, can be safe and feasible in selected cases as an alternative approach to the open surgery, offering good oncological and functional results.

Published
2021

20. Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy

Author

Gianluca Ragone, Carlo Buonerba, Ciro Imbimbo, Antonella Sciarra, Giuseppe Di Lorenzo, Roberto Sanseverino, Concetta Ingenito, Emilio Leo, Sabino De Placido, Annamaria Libroia, Felice Crocetto, Simona Iaccarino, Giorgio Napodano, Luciana Buonerba, Zisis Kozlakidis, Di Lorenzo, G, Buonerba, L, Ingenito, C, Crocetto, F, Buonerba, C, Libroia, A, Sciarra, A, Ragone, G, Sanseverino, R, Iaccarino, S, Napodano, G, Imbimbo, C, Leo, E, Kozlakidis, Z, De Placido, S, Di Lorenzo, G., Buonerba, L., Ingenito, C., Crocetto, F., Buonerba, C., Libroia, A., Sciarra, A., Ragone, G., Sanseverino, R., Iaccarino, S., Napodano, G., Imbimbo, C., Leo, E., Kozlakidis, Z., and De Placido, S.

Subjects
Oncology, Male, Cancer Research, medicine.medical_treatment, Disease, Comorbidities, Prostate cancer, 0302 clinical medicine, 030212 general & internal medicine, Androgen Antagonist, Aged, 80 and over, General Medicine, Middle Aged, Hospitalization, Prostatic Neoplasms, Castration-Resistant, Italy, 030220 oncology & carcinogenesis, Urologic cancer, Disease Progression, Hormonal therapy, Drug Therapy, Combination, Comorbiditie, Human, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Prognosi, Drug interaction, Coronavirus disease SARS-CoV-2, Pneumonia, Viral, Protective factor, Clinical Trial Note, 03 medical and health sciences, Internal medicine, medicine, Risk factor, Aged, Antiviral Agent, Chemotherapy, Betacoronaviru, Pandemic, business.industry, Coronavirus Infection, Heparin, SARS-CoV-2, Risk Factor, COVID-19, medicine.disease, business
Abstract

Background: To date, the clinical characteristics of coronavirus disease 19 (COVID-19)-infected urologic cancer patients are unknown. Methods: We have analyzed all patients with prostate cancer undergoing hormonal or chemotherapy treatment and receiving telephone and in person pre-triage between March 1 and 27, 2020, at the Tortora Hospital, Pagani, Italy. Results: Among 72 patients, 48 and 24 were hormone-sensitive (HS) and castration-resistant prostate cancer (CRPC), respectively; 0 HS and 2 (8.3%) CRPC (p < 0.05) were positive for COVID-19. Both patients were receiving LHRH agonist therapy, and 1 patient was receiving enzalutamide. Urgent intensive care unit admission was required due to clinical worsening. Blood tests showed severe lymphopenia, anemia, and an increase in platelets. Retroviral therapy, antibiotics, heparin, and chloroquine were prescribed at the beginning. One patient also received tocilizumab as a salvage treatment. After 3 weeks of hospitalization, the patients were discharged from the hospital. Both patients suffered from an aggressive COVID-19 course due to concomitant comorbidities. Conclusions: Investigating whether hormonal therapy, especially in advanced disease, acts as a protective factor or a risk factor during COVID-19 could be useful.

Published
2020

21. A Large Paraprostatic Mass in A Man: Rare Presentation of Aggressive Angiomyxoma

Author

Maria Addesso, Alessandro Caputo, Antonio D'Antonio, Giorgio Napodano, Roberto Sanseverino, Addesso, M., Caputo, A., D'Antonio, A., Napodano, G., and Sanseverino, R.

Subjects
Male, medicine.medical_specialty, Urology, 030232 urology & nephrology, Infiltrative Growth, 03 medical and health sciences, 0302 clinical medicine, Aggressive angiomyxoma, Rare case, medicine, Humans, Pelvis, Pelvic Neoplasms, Urinary symptoms, business.industry, Prostate, Middle Aged, medicine.disease, medicine.anatomical_structure, Male patient, 030220 oncology & carcinogenesis, Rare Lesion, Radiology, Presentation (obstetrics), business, Myxoma
Abstract

Aggressive angiomyxoma is a rare lesion with infiltrative growth and a tendency to recur locally. We present the images of a rare case of aggressive angiomyxoma in the pelvic region of a male patient presenting as a retrovesical, paraprostatic mass causing urinary symptoms.

Published
2020

22. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study

Author

Angelo, Porreca, Marianna, Noale, Walter, Artibani, Pier Francesco Bassi, Filippo, Bertoni, Sergio, Bracarda, Giario Natale Conti, Renzo, Corvò, Mauro, Gacci, Pierpaolo, Graziotti, Magrini, STEFANO MARIA, Vincenzo, Mirone, Rodolfo, Montironi, Giovanni, Muto, Stefano, Pecoraro, Umberto, Ricardi, Elvio, Russi, Andrea, Tubaro, Vittorina, Zagonel, Gaetano, Crepaldi, Stefania, Maggi, Pierfrancesco, Bassi, Stefano Maria Magrini, Anna Rita Alitto, Enrica, Ambrosi, Alessandro, Antonelli, Cynthia, Aristei, Michele, Barbieri, Franco, Bardari, Lilia, Bardoscia, Salvina, Barra, Sara, Bartoncini, Umberto, Basso, Carlotta, Becherini, Rita, Bellavita, Franco, Bergamaschi, Stefania, Berlingheri, Berruti, Alfredo, Marco, Borghesi, Roberto, Bortolus, Valentina, Borzillo, Davide, Bosetti, Giuseppe, Bove, Pierluigi, Bove, Maurizio, Brausi, Alessio, Bruni, Giorgio, Bruno, Eugenio, Brunocilla, Alberto, Buffoli, BUGLIONE DI MONALE E BASTIA, Michela, Consuelo, Buttigliero, Giovanni, Cacciamani, Michela, Caldiroli, Giuseppe, Cardo, Giorgio, Carmignani, Giuseppe, Carrieri, Emanuele, Castelli, Elisabetta, Castrezzati, Gianpiero, Catalano, Susanna, Cattarino, Francesco, Catucci, Francolini Dario Cavallini, Ofelia, Ceccarini, Antonio, Celia, Francesco, Chiancone, Tommaso, Chini, Claudia, Cianci, Antonio, Cisternino, Devis, Collura, Franco, Corbella, Matteo, Corinti, Paolo, Corsi, Fiorenza, Cortese, Luigi, Corti, Cosimo de Nunzio, Olga, Cristiano, Rolando, M D'Angelillo, Luigi Da Pozzo, Daniele, D'Agostino, Carolina, D'Elia, Matteo, Dandrea, Michele De Angelis, Paolo De Angelis, Ottavio De Cobelli, Bernardino De Concilio, Antonello De Lisa, Stefano De Luca, Agostina De Stefani, Chiara Lucrezia Deantoni, Esposti Claudio Degli, Anna, Destito, Beatrice, Detti, Nadia Di Muzio, Andrea Di Stasio, Calogero Di Stefano, Danilo Di Trapani, Giuseppe, Difino, Sara, Falivene, Giuseppe, Farullo, Paolo, Fedelini, Ilaria, Ferrari, Francesco, Ferrau, Matteo, Ferro, Andrei, Fodor, Francesco, Fontanta, Francesco, Francesca, Giulio, Francolini, Paolo, Frata, Giovanni, Frezza, Pietro, Gabriele, Maria, Galeandro, Elisabetta, Garibaldi, Pietro Giovanni Gennari, Alessandro, Gentilucci, Alessandro, Giacobbe, Laura, Giussani, Giuseppe, Giusti, Paolo, Gontero, Alessia, Guarneri, Cesare, Guida, Alberto, Gurioli, Dorijan, Huqi, Ciro, Imbimbo, Gianluca, Ingrosso, Cinzia, Iotti, Corrado, Italia, Pierdaniele La Mattina, Enza, Lamanna, Luciana, Lastrucci, Grazia, Lazzari, Fabiola, Liberale, Giovanni, Liguori, Roberto, Lisi, Frank, Lohr, Riccardo, Lombardo, Jon A, J Lovisolo, Giuseppe Mario Ludovico, Nicola, Macchione, Francesca, Maggio, Michele, Malizia, Gianluca, Manasse, Giovanni, Mandoliti, Giovanna, Mantini, Luigi, Marafioti, Luisa, Marciello, Alberto Mario Marconi, Antonietta, Martilotta, Salvino, Marzano, Stefano, Masciullo, Gloria, Maso, Adele, Massenzo, Ercole, Mazzeo, Luigi, Mearini, Serena, Medoro, Rosa, Molè, Giorgio, Monesi, Emanuele, Montanari, Franco, Montefiore, Giampaolo, Montesi, Giuseppe, Morgia, Gregorio, Moro, Giorgio, Muscas, Daniela, Musio, Paolo, Muto, Giovanni, Muzzonigro, Giorgio, Napodano, Carlo Luigi Augusto Negro, Mattia, Nidini, Maria, Ntreta, Marco, Orsatti, Carmela, Palazzolo, Isabella, Palumbo, Alessandro, Parisi, Paolo, Parma, Nicola, Pavan, Martina, Pericolini, Francesco, Pinto, Antonio, Pistone, Valerio, Pizzuti, Angelo, Platania, Caterina, Polli, Giorgio, Pomara, Elisabetta, Ponti, Antonio Benito Porcaro, Francesco, Porpiglia, Dario, Pugliese, Armin, Pycha, Giuseppe, Raguso, Andrea, Rampini, Donato Franco Randone, Valentina, Roboldi, Marco, Roscigno, Maria Paola Ruggieri, Giuseppe, Ruoppo, Roberto, Sanseverino, Anna, Santacaterina, Michele, Santarsieri, Riccardo, Santoni, Sarah, Scagliarini, Giorgio Vittorio Scagliotti, Mauro, Scanzi, Marcello, Scarcia, Riccardo, Schiavina, Alessandro, Sciarra, Carmine, Sciorio, Tindaro, Scolaro, Salvatore, Scuzzarella, Oscar, Selvaggio, Armando, Serao, Sergio, Serni, Marco Andrea Signor, Mauro, Silvani, Giovanni, Silvano, Franco, Silvestris, Simeone, Claudio, Valeria, Simone, Girolamo, Spagnoletti, Matteo Giulio Spinelli, Luigi, Squillace, Vincenzo, Tombolini, Mariastella, Toninelli, Triggiani, Luca, Alberto, Trinchieri, Luca Eolo Trodella, Lucio, Trodella, Carlo, Trombetta, Lidia, Tronnolone, Marcello, Tucci, Daniele, Urzì, Riccardo, Valdagni, Maurizio, Valeriani, Maurizio, Vanoli, Elisabetta, Vitali, Alessandro, Volpe, Stefano, Zaramella, Guglielmo, Zeccolini, Giampaolo, Zini, Porreca, Angelo, Noale, Marianna, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Ricardi, Umberto, Russi, Elvio, Tubaro, Andrea, Zagonel, Vittorina, Crepaldi, Gaetano, Maggi, Stefania, Gaetano, Crepaldi, Umberto, Basso, Luigi, Corti, D'Agostino, Daniele, Matteo, Dandrea, Davide, Bosetti, Gianpiero, Catalano, Ottavio, De Cobelli, Lucrezia, Deantoni Chiara, Nadia, Di Muzio, Ferro, Matteo, Andrei, Fodor, Pierdaniele, La Mattina, Emanuele, Montanari, Barbieri, Michele, Valentina, Borzillo, Chiancone, Francesco, Sara, Falivene, Paolo, Fedelini, Imbimbo, Ciro, Paolo, Muto, Sarah, Scagliarini, Giovanni, Muzzonigro, Enrica, Ambrosi, Alessandro, Antonelli, Lilia, Bardoscia, Stefania, Berlingheri, Alfredo, Berruti, Alberto, Buffoli, Michela, Buglione, Mauro, Scanzi, Elisabetta, Castrezzati, Paolo, Frata, Giulio, Francolini, Beatrice, Detti, Tommaso, Chini, Carlotta, Becherini, Olga, Cristiano, Cesare, Guida, Sara, Bartoncini, Consuelo, Buttigliero, Emanuele, Castelli, Devis, Collura, Stefano, De Luca, Pietro, Gabriele, Elisabetta, Garibaldi, Alessandro, Giacobbe, Paolo, Gontero, Alessia, Guarneri, Alberto, Gurioli, Francesco, Porpiglia, Franco, Randone Donato, Vittorio, Scagliotti Giorgio, Cynthia, Aristei, Rita, Bellavita, Isabella, Palumbo, Franco, Bardari, Augusto, Negro Carlo Luigi, Franco, Bergamaschi, Maria, Galeandro, Cinzia, Iotti, Giuseppe, Raguso, Paola, Ruggieri Maria, Giuseppe, Ruoppo, Marco, Borghesi, Eugenio, Brunocilla, Claudio, Degli Esposti, Giovanni, Frezza, Michele, Malizia, Maria, Ntreta, Alessandro, Parisi, Riccardo, Schiavina, Roberto, Bortolu, Giuseppe, Bove, Antonio, Cisternino, Carrieri, Giuseppe, Giuseppe, Difino, Oscar, Selvaggio, Maurizio, Brausi, Alessio, Bruni, Frank, Lohr, Ercole, Mazzeo, Enza, Lamanna, Calogero, Di Stefano, Giorgio, Bruno, Michela, Caldiroli, Ilaria, Ferrari, Laura, Giussani, Lovisolo Jon, A. J., Mario, Marconi Alberto, Giuseppe, Cardo, Mario, Ludovico Giuseppe, Marcello, Scarcia, Giorgio, Carmignani, Salvina, Barra, Dario, Cavallini Francolini, Franco, Corbella, Ofelia, Ceccarini, Luigi, Da Pozzo, Agostina, De Stefani, Corrado, Italia, Stefano, Masciullo, Valentina, Roboldi, Marco, Roscigno, Antonio, Celia, Bernardino, De Concilio, Claudia, Cianci, Francesco, Francesca, Giorgio, Pomara, Michele, Santarsieri, Fiorenza, Cortese, Andrea, Di Stasio, Franco, Montefiore, Armando, Serao, D'Elia, Carolina, Armin, Pycha, Dorijan, Huqi, Paolo, De Angeli, Nicola, Macchione, Francesco, Fontanta, Giorgio, Monesi, Antonello, De Lisa, Giuseppe, Giusti, Giorgio, Musca, Anna, Destito, Rosa, Molè, Danilo, Di Trapani, Francesco, Ferrau, Carmela, Palazzolo, Angelo, Platania, Anna, Santacaterina, Grazia, Lazzari, Fabiola, Liberale, Gregorio, Moro, Giovanni, Liguori, Nicola, Pavan, Francesca, Maggio, Marco, Orsatti, Giovanni, Mandoliti, Giampaolo, Montesi, Luigi, Marafioti, Antonietta, Martilotta, Adele, Massenzo, Luisa, Marciello, Salvino, Marzano, Caterina, Polli, Gloria, Maso, Serena, Medoro, Giuseppe, Morgia, Napodano, Giorgio, Pistone, Antonio, Roberto, Sanseverino, Mattia, Nidini, Paolo, Parma, Valerio, Pizzuti, Sciorio, Carmine, Scuzzarella, Salvatore, Tindaro, Scolaro, Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S, Crepaldi G, Maggi S, Noale M, Porreca A, Artibani W, Bassi P, Bracarda S, Conti GN, Corvò R, Graziotti P, Russi E, Mirone V, Montironi R, Bertoni F, Gacci M, Magrini SM, Muto G, Pecoraro S, Ricardi U, Tubaro A, Zagonel V, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini FD, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Nunzio C, Cristiano O, D'Angelillo RM, Da Pozzo L, D'agostino D, D'Elia C, Dandrea M, De Angelis M, De Angelis P, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli EC, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, Ferro M, Fodor A, Fontanta F, Francesca F, Francolini G, Frata P, Frezza G, Gabriele P, Galeandro M, Garibaldi E, Gennari PG, Gentilucci A, Giacobbe A, Giussani L, Giusti G, Gontero P, Guarneri A, Guida C, Gurioli A, Huqi D, Imbimbo C, Ingrosso G, Iotti C, Italia C, La Mattina P, Lamanna E, Lastrucci L, Lazzari G, Liberale F, Liguori G, Lisi R, Lohr F, Lombardo R, Lovisolo JAJ, Ludovico GM, Macchione N, Maggio F, Malizia M, Manasse G, Mandoliti G, Mantini G, Marafioti L, Marciello L, Marconi AM, Martilotta A, Marzano S, Masciullo S, Maso G, Massenzo A, Mazzeo E, Mearini L, Medoro S, Molè R, Monesi G, Montanari E, Montefiore F, Montesi G, Morgia G, Moro G, Muscas G, Musio D, Muto P, Muzzonigro G, Napodano G, Negro CLA, Nidini M, Ntreta M, Orsatti M, Palazzolo C, Palumbo I, Parisi A, Parma P, Pavan N, Pericolini M, Pinto F, Pistone A, Pizzuti V, Platania A, Polli C, Pomara G, Ponti E, Porcaro AB, Porpiglia F, Pugliese D, Pycha A, Raguso G, Rampini A, Randone DF, Roboldi V, Roscigno M, Ruggieri MP, Ruoppo G, Sanseverino R, Santacaterina A, Santarsieri M, Santoni R, Scagliarini S, Scagliotti GV, Scanzi M, Scarcia M, Schiavina R, Sciarra A, Sciorio C, Scolaro T, Scuzzarella S, Selvaggio O, Serao A, Serni S, Signor MA, Silvani M, Silvano G, Silvestris F, Simeone C, Simone V, Spagnoletti G, Spinelli MG, Squillace L, Tombolini V, Toninelli M, Triggiani L, Trinchieri A, Trodella LE, Trodella L, Trombetta C, Tronnolone L, Tucci M, Urzì D, Valdagni R, Valeriani M, Vanoli M, Vitali E, Volpe A, Zaramella S, Zeccolini G, Zini G, Porreca, A., Noale, M., Artibani, W., Bassi, P. F., Bertoni, F., Bracarda, S., Conti, G. N., Corvo, R., Gacci, M., Graziotti, P., Magrini, S. M., Mirone, V., Montironi, R., Muto, G., Pecoraro, S., Ricardi, U., Russi, E., Tubaro, A., Zagonel, V., Crepaldi, G., Maggi, S., Alitto, A. R., Ambrosi, E., Antonelli, A., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Maurizio, B., Alessio, B., Giorgio, B., Eugenio, B., Alberto, B., Michela, B., Consuelo, B., Giovanni, C., Michela, C., Giuseppe, C., Giorgio, C., Emanuele, C., Elisabetta, C., Gianpiero, C., Susanna, C., Catucci, F., Dario, C. F., Ofelia, C., Antonio, C., Francesco, C., Tommaso, C., Claudia, C., Devis, C., Franco, C., Matteo, C., Paolo, C., Fiorenza, C., Luigi, C., Cosimo, N., Cristiano, O., D'Angelillo, R. M., Da Pozzo, L., D'Agostino, D., D'Elia, C., Dandrea, M., De Angelis, M., De Angelis, P., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli, E. C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontanta, F., Francesca, F., Francolini, G., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari, P. G., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J. A. J., Ludovico, G. M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi, A. M., Martilotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone, D. F., Roboldi, V., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti, G. V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simeone, C., Simone, V., Spagnoletti, G., Spinelli, M. G., Squillace, L., Tombolini, V., Toninelli, M., Triggiani, L., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Volpe, A., Zaramella, S., Zeccolini, G., Zini, G., Porreca, A, Noale, M, Artibani, W, Bassi, P, Bertoni, F, Bracarda, S, Conti, G, Corvò, R, Gacci, M, Graziotti, P, Magrini, S, Mirone, V, Montironi, R, Muto, G, Pecoraro, S, Ricardi, U, Russi, E, Tubaro, A, Zagonel, V, Crepaldi, G, Maggi, S, and Da Pozzo, L

Subjects
Male, 030232 urology & nephrology, Severity of Illness Index, Prostate cancer, 0302 clinical medicine, Quality of life, Activities of Daily Living, Diagnosis, Medicine, Age Factor, Prospective Studies, Prospective cohort study, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Age Factors, Pros-IT CNR study, General Medicine, Health Survey, Middle Aged, Neoadjuvant Therapy, 3. Good health, Italy, 030220 oncology & carcinogenesis, lcsh:R858-859.7, Regression Analysis, Public Health, Human, Diagnosi, prostate cancer, survival, quality of life, medicine.medical_specialty, lcsh:Computer applications to medicine. Medical informatics, Regression Analysi, 03 medical and health sciences, Percutaneous Coronary Intervention, Internal medicine, Severity of illness, Humans, Aged, Cancer staging, business.industry, Research, Environmental and Occupational Health, Public Health, Environmental and Occupational Health, Prostatic Neoplasms, Cancer, medicine.disease, Health Surveys, Comorbidity, Quality of Life, Prospective Studie, Settore MED/24, Prostatic Neoplasm, business, Sexual function
Abstract

Background The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer is diagnosed. Methods One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12). Results At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one. Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower sexual function scores at diagnosis. Conclusions Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different profile of care.

Published
2018

23. MP18-18 COMPLICATIONS AFTER RANDOM TRUS GUIDED TRANSRECTAL PROSTATE BIOPSY

Author

T. Realfonso, Maria Addesso, Giorgio Napodano, Giovanni Molisso, Roberto Sanseverino, and Raffaele Baio

Subjects
medicine.medical_specialty, business.industry, Urology, Ultrasound, Gold standard (test), urologic and male genital diseases, medicine.disease, Prostate cancer, medicine.anatomical_structure, Prostate, medicine, Radiology, business, Transrectal Prostate Biopsy
Abstract

INTRODUCTION AND OBJECTIVES:Prostate biospy is the gold standard procedure to diagnose prostate cancer. The technique is usually performed under transrectal ultrasound (TRUS) guidance with transrec...

Published
2019

25. Diagnostic and Therapeutic Approach in Patients with Urinary Calculi

Author

Pasquale Strazzullo, Roberto Sanseverino, Bruno Baggio, Giuseppe Mossetti, Maurizio Terribile, Maurizio Prampolini, Anna Rita D’Angelo, Francesco Maria Drudi, Filiberto Zattoni, Antonio Novenne, Pier Giorgio Simeoni, Martino Marangella, Francesco Carrano, Giampaolo Bianchi, Alessandro D'Addessi, Elisa Cicerello, Salvatore Micali, Andrea Tasca, Marco Lombardi, Emanuele Croppi, Giuseppe Vezzoli, Renata Caudarella, Adamasco Cupisti, Sergio Cosciani-Cunico, Giovanni Muto, Alberto Trinchieri, and Giovanni Gambaro

Subjects
medicine.medical_specialty, Therapeutic approach, business.industry, Urinary system, Urology, medicine, In patient, General Medicine, business
Abstract

The natural history of urolithiasis includes the risk of recurrence and of the development of chronic kidney and/or bone disease, which is why a thorough clinical and metabolic evaluation of these patients is of the utmost importance at disease onset. This paper is aimed at identifying the type of urolithiasis, the related risk factors, and the corresponding treatment options. The diagnostic and therapeutic approach described here includes 1) accurate history taking to detect secondary nephrolithiasis and screen for the main risk factors for kidney and bone disease; 2) metabolic evaluation graded according to different complexity levels based on the severity of the disease and the presence of risk factors; 3) carrying out appropriate imaging procedures. The resulting information allows to plan treatment based either on general rules of lifestyle and diet, or on selected medical intervention, if necessary. This report, which is based on current guidelines, was produced by the Gruppo Italiano di Studio Multidisciplinare per la Calcolosi Renale. It is addressed to all professionals involved in the management of patients suffering from nephrolithiasis, first of all general practitioners, who often become involved immediately at the onset of the disease.

Published
2010

27. MP66-20 SIURO-PRIAS-ITA PROJECT: FIVE YEAR EXPERIENCE ON ACTIVE SURVEILLANCE

Author

Rocco Papalia, Michele Gallucci, Giario Conti, Giuseppe Martorana, Roberto Sanseverino, Ezio Frego, Marco Tanello, Pierpaolo Graziotti, Andrea Turci, Pasquale Ditonno, Maurizio Colecchia, Michelangelo Fiorentino, Rodolfo Montironi, Carlo Patriarca, Maria Rosa Raspollini, Tiziana Magnani, Chris Bangma, and Riccardo Valdagni

Subjects
Urology
Published
2015

28. [Clinical practice and adherence to the diagnosis and treatment of NMIBC guidelines: a report of a recognition based clinical cases study]

Author

Alberto Lapini, Roberto Sanseverino, Paolo Gontero, Vincenzo Serretta, Renzo Colombo, and Aldo Torreggiani

Subjects
Male, medicine.medical_specialty, Pathology, MEDLINE, Antineoplastic Agents, Disease, Epidemiology, medicine, Humans, Routine clinical practice, Intensive care medicine, Neoplasm Staging, Bladder cancer, business.industry, Carcinoma, General Medicine, Evidence-based medicine, Middle Aged, medicine.disease, Clinical Practice, Administration, Intravesical, Treatment Outcome, Urinary Bladder Neoplasms, Chemotherapy, Adjuvant, Practice Guidelines as Topic, BCG Vaccine, Guideline Adherence, business, Strengths and weaknesses
Abstract

For non-muscle invasive bladder cancer, a disease with a considerable epidemiological and socio-economic impact, the introduction of the Guidelines has always evoked as a tool for the resolution of long-standing disputes in terms of diagnosis and therapy. Check the degree of routine clinical practice adherence to the Recommendations is for this disease, more than for other uro-oncology pathology, an urgent need felt by the urological community. To assess the level of Guidelines adherence's, and study issues related to the paths of diagnosis and treatment of non-muscle invasive bladder cancer, and identifying the processes actually implemented in daily clinical practice, a series of case studies has submitted to a group of experts. The acknowledgement study allowed testing the impact of the current Evidence Based Medicine Recommendations in the everyday clinical practice identifying strengths and weaknesses. Questions Responses Analysis' of 5 clinical cases (Ta low grade, T1 low grade, T1 high grade, T1 high grade + CIS, Ta low-grade multiple recurrence) showed a moderate amendment to the European Association of Urology (EAU)-Guidelines. On the other hand, it was emphasized that there are clear discrepancies between what should be done, in accordance with the Evidence Based Medicine Recommendations, and what is actually do in everyday clinical practice. The most common reason for the low Recommendations adherences are structural and organizational practical limitations.

Published
2015

29. Observational Database Serenoa Repens (DOSSER): Overview, analysis and results

Author

Alessandro Bertaccini, Marco Giampaoli, Riccardo Cividini, Gian Luca Gattoni, Roberto Sanseverino, Tommaso Realfonso, Giorgio Napodano, Andrea Fandella, Elisa Guidoni, Raffaele Galasso, Carmine Cicalese, Vincenzo Scattoni, Angelo Armenio, Giario Conti, Matteo Corinti, Roberta Spasciani, Giovanni Liguori, Nikolitsa Lampropoulou, Giuseppe Martorana, PREZIOSO, DOMENICO, Alessandro, Bertaccini, Marco, Giampaoli, Riccardo, Cividini, Gian Luca, Gattoni, Roberto, Sanseverino, Tommaso, Realfonso, Giorgio, Napodano, Andrea, Fandella, Elisa, Guidoni, Prezioso, Domenico, Raffaele, Galasso, Carmine, Cicalese, Vincenzo, Scattoni, Angelo, Armenio, Giario, Conti, Matteo, Corinti, Roberta, Spasciani, Giovanni, Liguori, Nikolitsa, Lampropoulou, and Giuseppe, Martorana

Published
2012

31. V1086 ZERO ISCHEMIA LAPAROSCOPIC PARTIAL NEPHRECTOMY. PRELIMINARY EXPERIENCE

Author

Giorgio Napodano, Carmine Cicalese, Roberto Sanseverino, Umberto Di Mauro, Oliver Intilla, and Giuseppe Lubrano

Subjects
medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, medicine, Zero ischemia, Session (computer science), business, Nephrectomy, Surgery
Published
2013

32. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

Author

Christopher R. Chapple, Sebastiano Spatafora, Walter Artibani, Francesco Montorsi, Filiberto Zattoni, Andrea Tubaro, Giacomo Novara, Roberto Sanseverino, Novara, G, Tubaro, A, Sanseverino, R, Spatafora, S, Artibani, W, Zattoni, F, Montorsi, Francesco, and Chapple, Cr

Subjects
Nephrology, Male, Tamsulosin, medicine.medical_specialty, Indoles, male lower urinary tract symptoms, silodosin, prostatic hyeprplasia, alpha-blockers, α-blockers, alfa blockers, benign prostatic enlargement, Urology, Male lower urinary tract symptoms, MEDLINE, Prostatic Hyperplasia, Benign prostatic enlargement, alpha-Blockers, law.invention, Randomized controlled trial, Lower Urinary Tract Symptoms, law, Internal medicine, medicine, Humans, Randomized Controlled Trials as Topic, Sulfonamides, Dose-Response Relationship, Drug, business.industry, Male lower urinary tract, Silodosin, Prostatic enlargement, Treatment Outcome, Meta-analysis, Urological Agents, business, medicine.drug
Abstract

To perform a systematic review and meta-analysis of randomized clinical trials (RCTs) reporting the efficacy and safety of silodosin in the treatment of non-neurogenic male LUTS suggestive of benign prostatic enlargement. A systematic review searching multiple dataset for the term "silodosin". A meta-analysis was conducted using Review Manager software (Cochrane Collaboration, Oxford, UK). Our systematic search retrieved four studies summarizing the data of five RCTs. Silodosin was more effective than placebo with regard to mean change in all the parameters related to the IPSS and Q(max) (all p values < 0.0003). Adverse events (AE), abnormal ejaculation (AEj), and withdrawal due to AE were all more common with silodosin (all p values < 0.001). The prevalence of dizziness and adverse events other than AEj was similar with silodosin and placebo. Silodosin was more effective than tamsulosin 0.2 mg with regard to some IPSS-related parameters and Q(max) (p a parts per thousand currency sign 0.05). Silodosin and tamsulosin 0.4 mg were similarly effective in all the efficacy analyses. AEj was less common with tamsulosin 0.2 and 0.4 mg (p values < 0.00001); adverse events other than AEj were more common with tamsulosin 0.2 and 0.4 mg (p values a parts per thousand currency sign0.05). Silodosin was significantly more effective than placebo and tamsulosin 0.2 mg in improving symptoms and as effective as tamsulosin 0.4 mg. With regard to adverse events, AEj was more common with silodosin. All the adverse events other than AEj were significantly more common with tamsulosin 0.2 and 0.4 mg and as frequent with silodosin and placebo.

Published
2013

33. Erratum to: Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

Author

F. Montorsi, Andrea Tubaro, Walter Artibani, Filiberto Zattoni, Giacomo Novara, Roberto Sanseverino, Christopher R. Chapple, and Sebastiano Spatafora

Subjects
Gynecology, medicine.medical_specialty, business.industry, Urology, Male lower urinary tract, male lower urinary tract symptoms, Silodosin, Prostatic enlargement, law.invention, Randomized controlled trial, law, Meta-analysis, medicine, business, medicine.drug
Published
2013

34. Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it

Author

Elisa Mazzini, Massimo Perachino, Caterina Galetti, Andrea Fandella, Giovanni L. Pappagallo, Antonio Casarico, Roberto Sanseverino, Ciro Niro, Sebastiano Spatafora, and Rodolfo Hurle

Subjects
medicine.medical_specialty, Pathology, Evidence-based practice, business.industry, Urology, Hyperplasia, medicine.disease, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, Lower urinary tract symptoms, Internal medicine, medicine, business, Original Research
Abstract

Background: The first Italian national guidelines were developed by the Italian Association of Urologists and published in 2007. Since then, a number of new drugs or classes of drugs have emerged for the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), new data have emerged on medical therapy (monotherapies and combination therapies), new surgical techniques have come into practice, and our understanding of disease pathogenesis has increased. Consequently, a new update of the guidelines has become necessary. Methods: A structured literature review was conducted to identify relevant papers published between 1 August 2006 and 12 December 2010. Publications before or after this timeframe were considered only if they were recognised as important milestones in the field or if the literature search did not identify publications within this timeframe. The quality of evidence and strength of recommendations were determined according to the Grading of Recommendations Assessment, Development and Evaluation framework. Main findings: Decisions on therapeutic intervention should be based on the impact of symptoms on quality of life (QoL) rather than the severity of symptoms (International Prostate Symptom Score (IPSS) score). A threshold for intervention was therefore based on the IPSS Q8, with intervention recommended for patients with a score of at least 4. Several differences in clinical recommendations have emerged. For example, combination therapy with a 5α-reductase inhibitor plus α blocker is now the recommended option for the treatment of patients at risk of BPH progression. Other differences include the warning of potential worsening of cognitive disturbances with use of anticholinergics in older patients, the distinction between Serenoa repens preparations (according to the method of extraction), and the clearly defined threshold of prostate size for performing open surgery (>80 g). While the recommendations included in these guidelines are evidence based, clinical decisions should also be informed by patients’ clinical and physical circumstances, as well as patients’ preferences and actions. Conclusions: These guidelines are intended to assist physicians and patients in the decision-making process regarding the management of LUTS/BPH, and support the process of continuous improvement of the quality of care and services to patients.

Published
2012

35. Prognostic impact of ReTURB in high grade T1 primary bladder cancer

Author

Antonio Campitelli, Maria Addesso, Giorgio Napodano, and Roberto Sanseverino

Subjects
Male, medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, Antineoplastic Agents, Cystectomy, lcsh:RC870-923, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, ReTurb, medicine, Carcinoma, Humans, Progression-free survival, Pathological, Aged, Neoplasm Staging, Urine cytology, Carcinoma, Transitional Cell, Bladder cancer, medicine.diagnostic_test, business.industry, Cancer, Cystoscopy, Middle Aged, Prognosis, lcsh:Diseases of the genitourinary system. Urology, medicine.disease, Combined Modality Therapy, Surgery, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, BCG Vaccine, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Purpose: To evaluate whether pathological outcomes of ReTURB have a prognostic impact on recurrence and progression of primitive T1HG bladder cancer. Material and methods: Patients affected by primitive T1HG TCC of bladder underwent restaging TURB (ReTURB). Patients with muscle invasive disease at ReTURB underwent radical cystectomy; those with non-muscle invasive residual (NMI-RT) and those with no residual tumour (NRT) received an intravesical BCG therapy. We compared recurrence and progression in NMIRT patients and NRT patients at restaging TURB. Patients were followed every 3-6 months with cystoscopy and urine cytology. Results: 212 patients were enrolled in the study. At ReTURB, residual cancer was detected in 92 of 196 (46.9%) valuable patients: 14.3% of these were upstaged to T2. At follow up of 26.3 ± 22.8 months, there were differences in recurrence and progression rates between NRT and NMIRT patients: 26.9% and 45.3% (p < 0.001), 10.6% and 23.4% (p 0.03), respectively. Recurrence-free and progression-free survivals were significantly higher in NRT compared to NMIRT patients: 73.1% and 54.7% (p < 0.001), 89.4% and 76.6 (p 0.03), respectively. Conclusions: ReTURB allows to identify a considerable number of residual and understaged cancer. Patients with NMIRT on ReTURB have worse prognosis than those with NRT in terms of recurrence and progression free survival. These outcomes seem to suggest a prognostic impact of findings on ReTURB that could be a valid tool in management of high grade T1 TCC.

Published
2016

39. 1299 CAN SPLITTING TURP AND HIFU IN TWO SESSION REDUCE COMPLICATION RATE?

Author

Giorgio Napodano, Umberto Di Mauro, Olivier Intilla, Roberto Sanseverino, and T. Realfonso

Subjects
Biochemical recurrence, medicine.medical_specialty, business.industry, Urology, urologic and male genital diseases, medicine.disease, Group B, Prostate cancer, medicine.anatomical_structure, Patient tolerance, Prostate, Medicine, Complication rate, Stage (cooking), business, Psa nadir
Abstract

INTRODUCTION AND OBJECTIVES: To evaluate whether splitting TURP and Hifu in two session can reduce complication rate in patients with localized prostate cancer. METHODS: From November 2004 to September 2010, 103 patients affected by localized prostate cancer underwent HIFU following TURP. In 39 patients both procedures were performed in the same session (Group A); in 64 patients HIFU was delayed (Group B). Follow up included serial PSA measurements and prostate biopsies 6 months after the treatment in all patients. Biochemical recurrence was defined as PSA nadir 2ng/ml (ASTRO 2005 criteria). We have evaluated complication rate in the Group A and B. RESULTS: The mean age, PSA and prostate volume were 73.3 ( 5.4) years, 8.2 ( 19.3) ng/ml and 29 ( 8,3) cc, respectively. Mean procedure time was 128 minutes and mean hospitalization was 3.4 days. Complications occurred in 30 patients. Complication rate was not associated with clinical stage (T1 vs T2) (p0,67), Gleason score (p0,62), age (p0,2), prostate volume (p0,06), PSA (p0,9). Complications rate was lower when HIFU has been delayed after TURP (Group B) [see table]. Complications occurred in 61% (24/39) of Group A patients and in 9,3% (6/64) of Group B patients (p 0,001). No significant differences were seen between Group A and B patients in terms of clinical stage (p0,9), Gleason score (p0,2), prostate volume (p0,3), age (p0,4) and PSA (p0,46). CONCLUSIONS: Splitting TURP and HIFU in two different sessions seems to reduce postoperative complications and improve patient tolerance of the procedure. Longer follow up and larger patient population are needed to obtain more robust evidence.

Published
2011

40. P062 SIUrO-PRIAS-ITA project: Three year experience on active surveillance

Author

Gianluigi Taverna, Enrico Bollito, Riccardo Valdagni, M. Gallucci, Silvia Proietti, G. Cicchetti, Michelangelo Fiorentino, Rodolfo Montironi, Giario Conti, Maria Francesca Alvisi, M. Tanello, Davide Diazzi, Giorgio Napodano, Giuseppe Martorana, Maurizio Colecchia, Pierpaolo Graziotti, C. Patriarca, Chris H. Bangma, Tiziana Rancati, E. Frego, Rocco Papalia, A. Turci, Tiziana Magnani, Roberto Sanseverino, and Steno Sentinelli

Subjects
business.industry, Urology, medicine, Medical emergency, medicine.disease, business
Published
2013

42. V24 Laparoscopic partial nephrectomy with 'kidney inversion'

Author

U. Di Mauro, Giorgio Napodano, Carmine Cicalese, Roberto Sanseverino, Giovanni Molisso, and O. Intilla

Subjects
Nuclear magnetic resonance, business.industry, Urology, medicine.medical_treatment, Medicine, business, Inversion (discrete mathematics), Nephrectomy
Published
2014

45. VID.06: Laparoscopic Radical Prostatectomy: Step by Step Technique

Author

O. Intilla, T. Realfonso, U. Di Mauro, Giorgio Napodano, Roberto Sanseverino, and R. Angrisani

Subjects
medicine.medical_specialty, Laparoscopic radical prostatectomy, business.industry, Urology, medicine.medical_treatment, medicine, business, Surgery
Published
2008

48. PROGNOSTIC VALUE OF Re-TURB OF HIGH RISK NON INVASIVE BLADDER CANCER

Author

Giuseppe Contaldo, Antonio Campitelli, Antonio Barela, Giorgio Napodano, and Roberto Sanseverino

Subjects
Oncology, medicine.medical_specialty, Bladder cancer, business.industry, Urology, Internal medicine, Non invasive, medicine, medicine.disease, business, Value (mathematics)
Published
2008

50. V-06.07

Author

U. Di Mauro, Giorgio Napodano, A. Campitelli, R. Angrisani, O. Intilla, and Roberto Sanseverino

Subjects
Traditional medicine, business.industry, Urology, Medicine, business
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results